ImmunoBrain

Biotechnology ResearchIsrael11-50 Employees

ImmunoBrain is a clinical stage biopharmaceutical company transforming the fight against neurodegeneration and aging by targeting the immune system, restoring brain immune communications and boosting natural repair mechanisms. ImmunoBrain’s lead program is a proprietary antibody targeting the inhibitory immune checkpoint pathway PD-1/PD-L1, to treat Alzheimer's disease. 

ImmunoBrain's novel approach for the treatment of neurodegeneration is based on years of innovative, cutting-edge scientific discoveries made in the lab of Prof. Michal Schwartz at the Weizmann Institute of Science.

Sign up for free to view info

Email Format Employee directory